Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route

Eva Medina, Carlos A. Guzmán, Lothar H. Staendner, Mario P. Colombo, Paola Paglia

Research output: Contribution to journalArticle

Abstract

Recombinant Salmonella strains expressing heterologous antigens can be delivered by oral route triggering the elicitation of efficient antigen-specific humoral, T helper and cytotoxic responses. The potential of attenuated Salmonella spp. to trigger anti-tumor immunity was evaluated for the first time by using β-galactosidase (β-gal) as a model tumor-associated antigen (TAA). β-gal was expressed in a Salmonella typhimurium aroA vaccine carrier strain either constitutively or under the control of a promoter activated upon infection. Oral immunization with both vaccine prototypes resulted in the elicitation of β-gal specific humoral and cell-mediated immunity. Although both strains were able to trigger antigen-specific CTL, responses were more efficient when the expression was controlled by the promoter activated upon infection. The anti-tumor efficacy of the stimulated response was validated by challenging vaccinated animals with an aggressive fibrosarcoma transfected with β-gal, which operationally acts as a TAA. Both groups of vaccinated mice exhibited a significant reduction in tumor take and growth with respect to animals vaccinated with plasmidless carrier (p <0.05). However, the overall efficiency was better in the group in which β-gal was controlled by the in vivo-activated promoter (85% versus 54%; p <0.05).

Original languageEnglish
Pages (from-to)693-699
Number of pages7
JournalEuropean Journal of Immunology
Volume29
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Salmonella Vaccines
Immunity
Neoplasm Antigens
Salmonella
Vaccines
Galactosidases
Heterophile Antigens
Antigens
Neoplasms
Fibrosarcoma
Salmonella typhimurium
Infection
Cellular Immunity
Immunization
Growth

Keywords

  • Anti-tumor immunity
  • Live carrier
  • Oral vaccine
  • Salmonella typhimurium

ASJC Scopus subject areas

  • Immunology

Cite this

Salmonella vaccine carrier strains : Effective delivery system to trigger anti-tumor immunity by oral route. / Medina, Eva; Guzmán, Carlos A.; Staendner, Lothar H.; Colombo, Mario P.; Paglia, Paola.

In: European Journal of Immunology, Vol. 29, No. 2, 1999, p. 693-699.

Research output: Contribution to journalArticle

Medina, Eva ; Guzmán, Carlos A. ; Staendner, Lothar H. ; Colombo, Mario P. ; Paglia, Paola. / Salmonella vaccine carrier strains : Effective delivery system to trigger anti-tumor immunity by oral route. In: European Journal of Immunology. 1999 ; Vol. 29, No. 2. pp. 693-699.
@article{2317e3baaa9c43ae8d87c2f8218e6254,
title = "Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route",
abstract = "Recombinant Salmonella strains expressing heterologous antigens can be delivered by oral route triggering the elicitation of efficient antigen-specific humoral, T helper and cytotoxic responses. The potential of attenuated Salmonella spp. to trigger anti-tumor immunity was evaluated for the first time by using β-galactosidase (β-gal) as a model tumor-associated antigen (TAA). β-gal was expressed in a Salmonella typhimurium aroA vaccine carrier strain either constitutively or under the control of a promoter activated upon infection. Oral immunization with both vaccine prototypes resulted in the elicitation of β-gal specific humoral and cell-mediated immunity. Although both strains were able to trigger antigen-specific CTL, responses were more efficient when the expression was controlled by the promoter activated upon infection. The anti-tumor efficacy of the stimulated response was validated by challenging vaccinated animals with an aggressive fibrosarcoma transfected with β-gal, which operationally acts as a TAA. Both groups of vaccinated mice exhibited a significant reduction in tumor take and growth with respect to animals vaccinated with plasmidless carrier (p <0.05). However, the overall efficiency was better in the group in which β-gal was controlled by the in vivo-activated promoter (85{\%} versus 54{\%}; p <0.05).",
keywords = "Anti-tumor immunity, Live carrier, Oral vaccine, Salmonella typhimurium",
author = "Eva Medina and Guzm{\'a}n, {Carlos A.} and Staendner, {Lothar H.} and Colombo, {Mario P.} and Paola Paglia",
year = "1999",
doi = "10.1002/(SICI)1521-4141(199902)29:02<693::AID-IMMU693>3.0.CO;2-V",
language = "English",
volume = "29",
pages = "693--699",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Salmonella vaccine carrier strains

T2 - Effective delivery system to trigger anti-tumor immunity by oral route

AU - Medina, Eva

AU - Guzmán, Carlos A.

AU - Staendner, Lothar H.

AU - Colombo, Mario P.

AU - Paglia, Paola

PY - 1999

Y1 - 1999

N2 - Recombinant Salmonella strains expressing heterologous antigens can be delivered by oral route triggering the elicitation of efficient antigen-specific humoral, T helper and cytotoxic responses. The potential of attenuated Salmonella spp. to trigger anti-tumor immunity was evaluated for the first time by using β-galactosidase (β-gal) as a model tumor-associated antigen (TAA). β-gal was expressed in a Salmonella typhimurium aroA vaccine carrier strain either constitutively or under the control of a promoter activated upon infection. Oral immunization with both vaccine prototypes resulted in the elicitation of β-gal specific humoral and cell-mediated immunity. Although both strains were able to trigger antigen-specific CTL, responses were more efficient when the expression was controlled by the promoter activated upon infection. The anti-tumor efficacy of the stimulated response was validated by challenging vaccinated animals with an aggressive fibrosarcoma transfected with β-gal, which operationally acts as a TAA. Both groups of vaccinated mice exhibited a significant reduction in tumor take and growth with respect to animals vaccinated with plasmidless carrier (p <0.05). However, the overall efficiency was better in the group in which β-gal was controlled by the in vivo-activated promoter (85% versus 54%; p <0.05).

AB - Recombinant Salmonella strains expressing heterologous antigens can be delivered by oral route triggering the elicitation of efficient antigen-specific humoral, T helper and cytotoxic responses. The potential of attenuated Salmonella spp. to trigger anti-tumor immunity was evaluated for the first time by using β-galactosidase (β-gal) as a model tumor-associated antigen (TAA). β-gal was expressed in a Salmonella typhimurium aroA vaccine carrier strain either constitutively or under the control of a promoter activated upon infection. Oral immunization with both vaccine prototypes resulted in the elicitation of β-gal specific humoral and cell-mediated immunity. Although both strains were able to trigger antigen-specific CTL, responses were more efficient when the expression was controlled by the promoter activated upon infection. The anti-tumor efficacy of the stimulated response was validated by challenging vaccinated animals with an aggressive fibrosarcoma transfected with β-gal, which operationally acts as a TAA. Both groups of vaccinated mice exhibited a significant reduction in tumor take and growth with respect to animals vaccinated with plasmidless carrier (p <0.05). However, the overall efficiency was better in the group in which β-gal was controlled by the in vivo-activated promoter (85% versus 54%; p <0.05).

KW - Anti-tumor immunity

KW - Live carrier

KW - Oral vaccine

KW - Salmonella typhimurium

UR - http://www.scopus.com/inward/record.url?scp=0032992529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032992529&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1521-4141(199902)29:02<693::AID-IMMU693>3.0.CO;2-V

DO - 10.1002/(SICI)1521-4141(199902)29:02<693::AID-IMMU693>3.0.CO;2-V

M3 - Article

C2 - 10064087

AN - SCOPUS:0032992529

VL - 29

SP - 693

EP - 699

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 2

ER -